论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
三叶青作为潜在治疗炎症性肠病和结直肠癌候选药物的潜在作用及有效成分
Authors Chen C, Chen L, Zheng W, Dai Y
Received 27 January 2025
Accepted for publication 1 May 2025
Published 7 July 2025 Volume 2025:18 Pages 779—788
DOI https://doi.org/10.2147/OTT.S516341
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Lukas Hawinkels
Chaoying Chen, Lin Chen, Weifeng Zheng, Yiyang Dai
Department of Gastroenterology, The Fourth Affiliated Hospital ZheJiang University School of Medicine, Yiwu, Zhejiang, 322000, People’s Republic of China
Correspondence: Chaoying Chen, Email chaoyingchen2006@163.com
Abstract: Inflammatory bowel disease (IBD) is a family of chronic inflammatory diseases such as Crohn’s disease (CD) and ulcerative colitis (UC). Among the serious malignancies that can arise from IBD, colorectal cancer is particularly prevalent. Individuals suffering from both IBD and CRC often endure similar symptoms, which include diarrhea, rectal bleeding, abdominal discomfort, weight decline, and profound exhaustion. Sanyeqing is a traditional herbaceous medicinal plant with anti-tumor, anti-inflammatory, analgesic, heat-clearing, detoxifying, and liver-protecting effects. Here, we summarize the possible molecular mechanisms of IBD and CRC, and summarize the potential role of Sanyeqing in clinical therapy for IBD and CRC. Investigating the etiology of enteritis and intestinal cancer, as well as exploring Sanyeqing’s potential as a preventive and therapeutic agent, is of paramount importance in the battle against these diseases.
Keywords: inflammatory bowel disease, colorectal cancer, sanyeqing, anti-inflammatory, anti-tumor